PAREXEL EXPERTS TO PRESENT LEADING INSIGHTS REGARDING KEY INDUSTRY TOPICS AT 22ND ANNUAL DIA EUROMEETING
Boston, MA, March 2, 2010 Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will address important industry issues at the Drug Information Association (DIA) 22nd Annual EuroMeeting, being held from March 8-10, 2010 in Monaco. A number of PAREXEL's thought leaders will present on topics ranging from risk-based contracted services relationship models, managing the end of patent, and improving submission success to ensuring therapeutic equivalence and developing borderline medical devices. Presentations from PAREXEL's subsidiary, Perceptive Informatics, a leading eClinical solutions provider, will address leveraging technology for Patient-Reported Outcomes (PROs) as well as the benefits and challenges of adaptive trials. PAREXEL experts will also be available during the meeting to address other key industry issues.
Complimentary advisories on key topics, including Top Post-Approval European Union (EU) Variation Considerations based on new European Commission Guidance, Top Five International Considerations for ePRO, and International Pharmacovigilance Guidelines, will be provided at PAREXEL’s Stands #108-110 and #118-119 in the exhibit hall. Attendees to PAREXEL’s stands will be able to view demonstrations of systems in the eClinical Suite from Perceptive Informatics, including the IMPACT® Clinical Trial Management System (CTMS), the DataLabs® EDC solution, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies. Providing interoperability among systems, the eClinical Suite supports real-time data interchange and enables diverse applications to work synergistically.
The DIA EuroMeeting program features the following sessions, which will be presented by PAREXEL experts:
Tuesday, March 9
• Accelerate Decision Making Through Real Time Dictionary Coding – Douglas Burgener, Product Manager Data Management Solutions, Perceptive Informatics (11:00)
• Risk-Based Contracted Services Relationship Model – Clive Brading, Senior Director, PAREXEL Consulting (14:00)
Wednesday, March 10
• Adaptive Trials: Too Complicated for Too Little Return? – Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics (9:00)
• Leveraging Technology in the Collection of PROs and ClinROs – Keith Wenzel, Senior Director, Product Management, Perceptive Informatics (9:00)
• Juvenile Animal Studies: When, Why, and What are You Going to Do with the Data? – Anders Neil, Ph.D., Principal Consultant, PAREXEL Consulting (9:00)
• Lessons from the Coalface – Scientific Advice as a Commercial Tool to Minimize Risk and Improve Submission Success – Peter Lassoff, Pharm D, Vice President, Europe, PAREXEL Consulting (9:00)
• How Do You Ensure Therapeutic Equivalence with Sufficient Confidence? – Cecil Nick, B.Sc.(Hons), Vice President, Biotechnology, PAREXEL Consulting (11:00)
• Managing the End of Patent for Medicinal Products: Overview of CMC/Quality Strategies – Hoss Dowlat, Vice President, Global Strategy, PAREXEL Consulting (14:00)
• Borderline Medical Devices – Medical Products – Peter Lassoff, Pharm D, Vice President, Europe, PAREXEL Consulting (14:00)
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 9,200 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings, including the anticipated restructuring charge of approximately $30 million over the second and third quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2009 as filed with the SEC on February 5, 2010, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.